Synergy CHC Faces $2.9M Revenue Hit as Gravity Pharma Ends Key Brand License
SNYR is trading near its 52-week low of $1.27 (4.7% above the low).
Summary
Gravity Pharma has terminated its Brand License Agreement with Synergy CHC, covering FOCUSfactor and Flat Tummy Co. in the UAE and Turkey. This agreement, which had an aggregate license fee of $2.9 million, was previously recognized as revenue by Synergy CHC. The termination is a highly material event for Synergy CHC, representing a significant portion of its approximately $15 million market capitalization, and will likely result in a substantial revenue reversal or loss of future revenue. Traders should monitor the company's financial disclosures for the precise impact and watch for updates on Synergy CHC's stated intent to continue pursuing registration and marketing of the licensed IP in the affected territories.
At the time of this announcement, SNYR was trading at $1.33 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $15M. The 52-week trading range was $1.27 to $4.08. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.